In exchange for a $20 million upfront payment and up to $212.5 million in milestones, Italy-based Angelini will gain exclusive development, manufacturing and commercialzation rights in Europe for OV101, a drug for Angelman syndrome.
Despite being separated by a big body of water and quite a few language barriers, there are few shared struggles in healthcare between the US and Europe. An Economist article highlighting the rise of telemedicine in the European Union calls attention to the issue of reimbursement and implementation in its member countries. As the article […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.